Nisa Investment Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-75
| Closed | -$119 | – | 3010 |
|
|
2024
Q1 | $119 | Hold |
75
| – | – | ﹤0.01% | 2701 |
|
|
2023
Q4 | $64 | Sell |
75
-1,075
| -93% | -$944 | ﹤0.01% | 2625 |
|
|
2023
Q3 | $1.23K | Hold |
1,150
| – | – | ﹤0.01% | 2369 |
|
|
2023
Q2 | $2.98K | Sell |
1,150
-74
| -6% | -$264 | ﹤0.01% | 2349 |
|
|
2023
Q1 | $5K | Sell |
1,224
-1,729
| -59% | -$7.99K | ﹤0.01% | 2249 |
|
|
2022
Q4 | $15K | Buy |
2,953
+1,803
| +157% | +$11.3K | ﹤0.01% | 2128 |
|
|
2022
Q3 | $6K | Sell |
1,150
-374
| -25% | -$5.66K | ﹤0.01% | 2276 |
|
|
2022
Q2 | $20K | Buy |
1,524
+1,150
| +307% | +$15.9K | ﹤0.01% | 2055 |
|
|
2022
Q1 | $6K | Sell |
374
-6,547
| -95% | -$102K | ﹤0.01% | 2299 |
|
|
2021
Q4 | $109K | Buy |
6,921
+4,032
| +140% | +$77.4K | ﹤0.01% | 1486 |
|
|
2021
Q3 | $61 | Sell |
2,889
-7,210
| -71% | -$159K | ﹤0.01% | 1889 |
|
|
2021
Q2 | $199 | Buy |
10,099
+2,000
| +25% | +$46.8K | ﹤0.01% | 1414 |
|
|
2021
Q1 | $235 | Hold |
8,099
| – | – | ﹤0.01% | 1433 |
|
|
2020
Q4 | $245K | Buy |
8,099
+5,157
| +175% | +$113K | ﹤0.01% | 1384 |
|
|
2020
Q3 | $47K | Sell |
2,942
-3,149
| -52% | -$57.4K | ﹤0.01% | 1833 |
|
|
2020
Q2 | $120K | Buy |
6,091
+228
| +4% | +$4.36K | ﹤0.01% | 1402 |
|
|
2020
Q1 | $72K | Hold |
5,863
| – | – | ﹤0.01% | 1460 |
|
|
2019
Q4 | $108K | Hold |
5,863
| – | – | ﹤0.01% | 1428 |
|
|
2019
Q3 | $81K | Buy |
+5,863
| New | +$88K | ﹤0.01% | 1488 |
|
Nisa Investment Advisors's NGM Position: Q2 2024 in Review
Nisa Investment Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 75 shares — an estimated $119 sold.
Nisa Investment Advisors first reported a position in NGM in Q3 2019 and held it in 19 quarters. The position peaked at $245K in Q4 2020. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Nisa Investment Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Nisa Investment Advisors sold 75 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $119.
- Nisa Investment Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 19 quarters.
- Nisa Investment Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $245K in Q4 2020.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Nisa Investment Advisors's 13F filing for Q2 2024, filed 19 Jul 2024.